Global Anti-Obesity Drugs Market to Reach $4.8 Billion by 2030

ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, March 15, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anti-Obesity Drugs Industry" - https://www.reportlinker.com/p06050508/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Anti-Obesity Drugs Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Anti-Obesity Drugs estimated at US$2.5 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at aCAGR of 8.4% over the period 2022-2030. Prescription Drugs, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the OTC Drugs segment is readjusted to a revised 11.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $750.4 Million, While China is Forecast to Grow at 7.5% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$750.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Select Competitors (Total 23 Featured)
- Eisai Co. Ltd. (Japan)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline Plc
- Novo Nordisk A/S (Denmark)
- Rhythm Pharmaceuticals (US)
- VIVUS Inc. (US)


Read the full report: https://www.reportlinker.com/p06050508/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Obesity and Overweight Statistics
Recent Market Activity
Obesity - A Prelude
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
Currently Available Anti-Obesity Medications
Select Currently Available Short-term and Long-term Anti-
Obesity Medication
Select Off-Label Drugs for Obesity
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus
to Market Growth
Semaglutide: Highest Potential in the AOM Pipeline
Setbacks of Past Drugs
Positive Road Ahead for Belviq
Relaunch of Xenical
Relaunch of Contrave®
Reluctance among Patients, Physicians, and Payers Hurts Market
Prospects
New Drug Development - High on the Agenda, Despite the Market
Restraints
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity
Drugs Space
Competitive Landscape
Novo Nordisk - The Leading Player in the Market
The United States - The Largest Obesity and Anti-Obesity Market
Europe - A Market with Vast Potential
Obesity Creeps Up in Developing Countries
Anti-Obesity Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (USA)
VIVUS, Inc. (USA)

3. MARKET TRENDS & DRIVERS
Alarming Rise in Global Obesity Levels - The Major Growth Factor
Classification of BMI
Rising Incidence of Chronic Diseases Associated with Obesity
Drive the Market Expansion
Growing Middle Class Population to Drive the Market Growth
Childhood Obesity - A Market with Unmet Needs
Commercial Weight-Loss Companies Foray into the Market
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions - A Barrier to Entry?
High Drug Development Costs - A Major Setback
Weight Loss Alternatives - A Market Dampener

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR

Table 2: World 8-Year Perspective for Anti-Obesity Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2023 & 2030

Table 3: World Recent Past, Current & Future Analysis for
Prescription Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR

Table 4: World 8-Year Perspective for Prescription Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for OTC
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2022 through 2030 and
% CAGR

Table 6: World 8-Year Perspective for OTC Drugs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2023 & 2030

Table 7: World Anti-Obesity Drugs Market Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 8: USA Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 9: USA 8-Year Perspective for Anti-Obesity Drugs by Type -
Percentage Breakdown of Value Sales for Prescription Drugs
and OTC Drugs for the Years 2023 & 2030

CANADA
Table 10: Canada Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 11: Canada 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

JAPAN
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 12: Japan Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 13: Japan 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

CHINA
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 14: China Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 15: China 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

EUROPE
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 16: Europe Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2022 through 2030 and %
CAGR

Table 17: Europe 8-Year Perspective for Anti-Obesity Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2023 & 2030

Table 18: Europe Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 19: Europe 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

FRANCE
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 20: France Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 21: France 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

GERMANY
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 22: Germany Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 23: Germany 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

ITALY
Table 24: Italy Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 25: Italy 8-Year Perspective for Anti-Obesity Drugs by
Type - Percentage Breakdown of Value Sales for Prescription
Drugs and OTC Drugs for the Years 2023 & 2030

UNITED KINGDOM
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 26: UK Recent Past, Current & Future Analysis for
Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 27: UK 8-Year Perspective for Anti-Obesity Drugs by Type -
Percentage Breakdown of Value Sales for Prescription Drugs
and OTC Drugs for the Years 2023 & 2030

REST OF EUROPE
Table 28: Rest of Europe Recent Past, Current & Future Analysis
for Anti-Obesity Drugs by Type - Prescription Drugs and OTC
Drugs - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR

Table 29: Rest of Europe 8-Year Perspective for Anti-Obesity
Drugs by Type - Percentage Breakdown of Value Sales for
Prescription Drugs and OTC Drugs for the Years 2023 & 2030

ASIA-PACIFIC
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 30: Asia-Pacific Recent Past, Current & Future Analysis
for Anti-Obesity Drugs by Type - Prescription Drugs and OTC
Drugs - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR

Table 31: Asia-Pacific 8-Year Perspective for Anti-Obesity
Drugs by Type - Percentage Breakdown of Value Sales for
Prescription Drugs and OTC Drugs for the Years 2023 & 2030

REST OF WORLD
Table 32: Rest of World Recent Past, Current & Future Analysis
for Anti-Obesity Drugs by Type - Prescription Drugs and OTC
Drugs - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR

Table 33: Rest of World 8-Year Perspective for Anti-Obesity
Drugs by Type - Percentage Breakdown of Value Sales for
Prescription Drugs and OTC Drugs for the Years 2023 & 2030

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06050508/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001